Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Compliance for Peptide Therapy and BPC 157 Holt Law September 8, 2025: FDA launches an import alert listing safe GLP 1 manufacturers Partnership for Safe Medicines